Interim Results

Summary by AI BETAClose X

CRISM Therapeutics Corporation reported a loss of £1.413 million for the six months ended 30 June 2026, an increase from the £0.93 million loss in the prior year's period, with administration expenses rising to £1.52 million. The company advanced its ChemoSeed™ technology, commencing patient recruitment for a Phase 2 glioblastoma trial and receiving significant grants totaling £996,000 from Innovate UK and Invest Northern Ireland. CRISM also secured FDA orphan drug designation for its irinotecan-ChemoSeed, and its cash position strengthened to £2.269 million as of 30 June 2026 following a £2.745 million fundraising.

Disclaimer*

UK 100

Latest directors dealings